FONAZINE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H25N3O2S2
Molecular Weight	391.551
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(CN1C2=C(SC3=C1C=C(C=C3)S(=O)(=O)N(C)C)C=CC=C2)N(C)C

InChI

InChIKey=VWNWVCJGUMZDIU-UHFFFAOYSA-N

InChI=1S/C19H25N3O2S2/c1-14(20(2)3)13-22-16-8-6-7-9-18(16)25-19-11-10-15(12-17(19)22)26(23,24)21(4)5/h6-12,14H,13H2,1-5H3

HIDE SMILES / InChI

Molecular Formula	C19H25N3O2S2
Molecular Weight	391.551
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.mufel.net/plm05/6816.htm
Curator's Comment: description was created based on several sources, including, https://www.jstage.jst.go.jp/article/gnam1977/3/2/3_113/_pdf, http://www.ncbi.nlm.nih.gov/pubmed/8564192

Fonzine (also known as dimetotiazine) is an analgesics and anti-inflammatory agent marketed in Japan and Europe under the name Migristene and indicated for the treatment of migraine and headaches secondary to other disease. Fonzine exerts its activity by inhibiting serotonin and histamine H1 receptors.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin (5-HT) receptor 34 Target ID: CHEMBL2096904 Sources: https://www.jstage.jst.go.jp/article/gnam1977/3/2/3_113/_pdf	Antagonist 2849
Histamine H1 receptor 316 Target ID: P35367 Gene ID: 3269.0 Gene Symbol: HRH1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/8564192	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Migraine 107 Sources: http://www.mufel.net/plm05/6816.htm	Primary		Approved 8583	MIGRISTENE Approved Use Prophylactic and curative treatment of migraine and headaches secondary other diseases.
Secondary headache 3 Sources: http://www.mufel.net/plm05/6816.htm	Primary		Approved 8583	MIGRISTENE Approved Use Prophylactic and curative treatment of migraine and headaches secondary other diseases.

PubMed

Title	Date	PubMed
Determination of isothipendyl or dimethothiazine with their sulphoxides using third- and fourth-derivatives spectroscopy on a diode-array spectrophotometer.	1990-07-01	2290121
[Clinical use of dimetotiazine (8599RP)].	1967-12-10	5593375
[Resorption, excretion and biotransformation of 3-dimethylsulfamido-10-(2-dimethylaminopropyl)-phenothiazine (Dimetotiazine) in the rabbit and dog].	1967-09-01	5583624

Patents

Sample Use Guides

In Vivo Use Guide

Take 20-80 mg during the first day (2-4 tablets) and then - 40 mg/day (2 tablets) up to 3 months.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:43:47 GMT 2025` Edited by `admin` on `Mon Mar 31 18:43:47 GMT 2025`
Record UNII	1FTA475ZDB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DIMETOTIAZINE

Preferred Name

English

FONAZINE

Common Name

English

DIMETHOTHIAZINE

Common Name

English

dimetotiazine [INN]

Common Name

English

Dimetotiazine [WHO-DD]

Common Name

English

MIGRISTENE

Brand Name

English

8599 R.P.

Code

English

IL-6302

Code

English

10-(2-(DIMETHYLAMINO)PROPYL)-N,N-DIMETHYLPHENOTHIAZINE-2-SULFONAMIDE

Systematic Name

English

FONAZINE [MI]

Common Name

English

PHENOTHIAZINE-2-SULFONAMIDE, 10-(2-(DIMETHYLAMINO)PROPYL)-N,N-DIMETHYL-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66885